Equity Insider News Commentary - Artificial intelligence has moved from the edges of drug discovery to its center. The biggest pharmaceutical companies in the world are now racing to design molecules with machine learning rather than trial and error, and the market has begun to reward the names building the infrastructure underneath that shift. MindWalk Holdings Corp. (NASDAQ: HYFT), a self-described Bio-Native AI company based in Austin, is one of the smaller players staking out a differentiate